NASDAQ:PCRX • US6951271005
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PACIRA BIOSCIENCES INC (PCRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-26 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-09 | Needham | Maintains | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Equal-Weight |
| 2025-11-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-09 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-28 | Needham | Maintains | Buy -> Buy |
| 2025-02-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-30 | Truist Securities | Upgrade | Sell -> Hold |
| 2025-01-14 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-01-13 | Needham | Maintains | Buy -> Buy |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-08 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-09-24 | Jefferies | Maintains | Buy -> Buy |
| 2024-08-13 | Truist Securities | Downgrade | Buy -> Sell |
| 2024-08-12 | Needham | Maintains | Buy -> Buy |
| 2024-08-12 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-08-12 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 674.978M 1.23% | 700.966M 3.85% | 726.411M 3.63% | 777.98M 7.10% | 849.17M 9.15% | 979.63M 15.36% | 956.59M -2.35% | 969.38M 1.34% | 969.51M 0.01% | 952.26M -1.78% | 748.37M -21.41% | |
| EBITDA YoY % growth | 166.321M 2.41% | 180.816M 8.72% | 129.701M -28.27% | 213.65M 64.73% | 250.89M 17.43% | 274.99M 9.61% | 286.11M 4.04% | 261.94M -8.45% | N/A | N/A | N/A | |
| EBIT YoY % growth | 90.747M 27.99% | 102.031M 12.43% | 38.678M -62.09% | 172.83M 346.84% | 209.64M 21.30% | 360.88M 72.14% | 267.05M -26.00% | 287.92M 7.82% | 390.9M 35.77% | 242.12M -38.06% | N/A | |
| Operating Margin | 13.44% | 14.56% | 5.32% | 22.22% | 24.69% | 36.84% | 27.92% | 29.70% | 40.32% | 25.43% | N/A | |
| EPS YoY % growth | 2.92 12.74% | 3.21 9.93% | 2.63 -18.07% | 3.07 16.65% | 3.83 24.67% | 3.92 2.49% | 4.38 11.62% | 4.36 -0.35% | 3.56 -18.36% | 4.36 22.35% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.60 -3.63% | 0.70 -5.31% | 0.68 -2.84% | 0.69 20.90% | 0.77 28.03% | 0.86 22.27% | 0.93 36.47% | 1.01 46.54% |
| Revenue Q2Q % growth | 178.56M 5.70% | 194.14M 7.20% | 195.1M 8.68% | 209.34M 6.33% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 41.316M 29.03% | 49.452M -16.30% | 47.565M -42.97% | 46.026M -51.34% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 36.414M 235.55% | 41.31M 290.08% | 31.824M 131.82% | 40.29M 1,032.06% | N/A | N/A | N/A | N/A |
All data in USD
13 analysts have analysed PCRX and the average price target is 29.58 USD. This implies a price increase of 29.28% is expected in the next year compared to the current price of 22.88.
PACIRA BIOSCIENCES INC (PCRX) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of PACIRA BIOSCIENCES INC (PCRX) is 0.6 USD and the consensus revenue estimate is 178.56M USD.
The number of analysts covering PACIRA BIOSCIENCES INC (PCRX) is 13.